For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...

no use impacts the odds for outcomes following transplantation. Of the total cohort, 34 had GLP-1 RA use in the outlined time frame (mean time to initiation, 318 days), with 23 patients prescribed ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort ...

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...

The authors used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated a GLP-1 RA and compared them to patients initiating sulfonylureas ...